Nasdaq · CIK 0001716166
VVOS Vivos Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 24 d ago.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
4
with a Form 4 at this company
Signals
Open-market buys and sells at Vivos Therapeutics, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 6 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | Leonard J Sokolow director | AGrant or award Stock Options (Right to Buy)derivative | +12,000 | $0.00 | $0 | 17,600 | 24 d ago |
| Sep 14, 2026 | Gregg C Johnson director | AGrant or award Stock Options (Right to Buy)derivative | +12,000 | $0.00 | $0 | 12,000 | 24 d ago |
| Jun 30, 2026 | Ronald Kirk Huntsman Chief Executive Officer | JOther Preferred Stockindirect: See footnote | +85,910 | $0.58 | $50k | 85,910 | 24 d ago |
| Jun 30, 2026 | Ronald Kirk Huntsman Chief Executive Officer | JOther Warrant (Right to Buy)derivativeindirect: See footnote | +85,910 | $0.58 | $50k | 85,910 | 24 d ago |
| Nov 26, 2024 | Bradford K. Amman Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +149,533 | $2.64 | $395k | 180,533 | Nov 27, 2024 |
| Nov 26, 2024 | Ronald Kirk Huntsman Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +315,421 | $2.64 | $833k | 364,755 | Nov 27, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Bradford K. AmmanChief Financial Officer
- Ronald Kirk HuntsmanChief Executive Officer
- Gregg C Johnsondirector
- Leonard J Sokolowdirector, ceo, officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.